ESPREsperion Therapeutics, Inc.
Sign up free
Thesis

ArchiMed closes $1.1B take-private of bempedoic acid franchise; CVR holders bet on 2027-2030 net sales milestones

Updated 64d ago

Esperion is a commercial-stage pharmaceutical company whose lead product, bempedoic acid for cholesterol management, is already approved and on the market.

Esperion was acquired by ArchiMed on July 13, 2026 for $3.16 per share cash plus CVRs worth up to $100 million tied to bempedoic acid and bumetanide net sales through 2030. The residual investable question is whether those sales milestones are achieved, contingent on commercial uptake sustaining after delisting and private operation. The CVR structure carries no recourse if milestones are missed, and the company no longer operates as a public equity.

Status
Broken
Conviction

Current Thesis Drivers

  • FY2025 revenue $403.1M, up 21%; 90%+ payer coverage achieved
  • ANDA settlements restrict generic entry until April 2040
  • CVR up to $100M aggregate tied to 2027-2030 net sales milestones
  • Merger closed July 13, 2026; public equity extinguished at $3.16/share

What could change the thesis?

  • CVR milestones 2027-2030: sales targets met pays out, missed forfeits all contingent value

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the thesis, argued

Pipeline

3 programs · 3 catalysts

Stress Test